AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🌍 Showing

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Condition

Country

City (shown first)

30 recruiting trials

for Advanced Biliary Tract Carcinoma

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors NCT05733000Phase 21 site📍 Chicago Northwestern University · Tests: Biospecimen Collection, Computed Tomography, Devimistat, Fluorouracil, Gemcitabine Hydrochloride Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma NCT07780838Phase 21 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Biospecimen Collection, Cisplatin, Computed Tomography, Durvalumab, Gemcitabine Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer NCT07392541Phase 1, Phase 21 site📍 Wuhan Tongji Hospital · Tests: Adebrelimab, Gemcitabine + Cisplatin, Simvastatin 20mg A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract Cancer NCT07850791Phase 21 site📍 Beijing Haitao Zhao, MD · Tests: Sacituzumab Tirumotecan (SKB264), Pembrolizumab Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor Ligufalimab and Cadonilimab in Advanced Liver Cancers NCT06789848Phase 21 site📍 Dallas University of Texas Southwestern Medical Center · Tests: Ligufalimab, Cadonilimab Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer NCT07614061Phase 11 site📍 Shanghai Shanghai Zhongshan Hospital · Tests: BTC-Ag-T (ACH-AgT001), Cyclophosphamide and Fludarabine A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors NCT07277413Phase 123 sites📍 Goodyear📍 Phoenix📍 Duarte IDEAYA Biosciences · Tests: IDE892, IDE397 Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) NCT05482893Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Denver Phanes Therapeutics · Tests: Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab) A Phase 1 Study of LNCB74 in Advanced Solid Tumors NCT06774963Phase 114 sites📍 Newport Beach📍 Edgewood📍 Boston NextCure, Inc. · Tests: LNCB74 Observational Study Protocol: LIVER-R NCT06252753n/a160 sites📍 Birmingham📍 Mobile📍 Phoenix AstraZeneca · Tests: Durvalumab-based combination therapies in observational study setting, Durvalumab-based combination therapies in observ… Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer NCT06708858Phase 21 site📍 Beijing Dai, Guanghai · Tests: Surufatinib, Gemcitabine, Cisplatin, Durvalumab, Pembrolizumab Registry for Advanced Endoscopy NCT05187312n/a1 site📍 Stockholm Region Stockholm · Tests: Endoscopic retrograde Cholangio- pancreatography, Endoscopic ultrasound Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer NCT07159204Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Paclitaxel polymer micelle immunocombination Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors NCT07334119Phase 17 sites📍 Darlinghurst📍 Randwick📍 Waratah Myeloid Therapeutics · Tests: MT-304, MT-304 + Nivolumab Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy NCT05222971Phase 21 site📍 Seoul Asan Medical Center · Tests: Durvalumab, Olaparib Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab NCT06648057n/a1 site📍 Seongnam-si CHA University · Tests: lenvatinib plus pembrolizumab Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors NCT05784688Phase 1, Phase 211 sites📍 San Antonio📍 Tyler📍 Spokane TiumBio Co., Ltd. · Tests: TU2218 + KEYTRUDA® (Pembrolizumab) Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer NCT06893380n/a1 site📍 Seongnam-si CHA University · Tests: Gemcitabine, Cisplatin, Nab-paclitaxel, and Tislelizumab. A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) NCT07229625Phase 31 site📍 Hangzhou Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-8068 Injection, Adebrelimab Injection, Gemcitabine Hydrochloride for Injection, Cisplatin Injection, Durvalumab Inj… Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors NCT06239194Phase 1, Phase 26 sites📍 Denver📍 Miami📍 Boston ModeX Therapeutics, An OPKO Health Company · Tests: MDX2001 Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB) NCT06712420Phase 33 sites📍 Delhi📍 Delhi📍 Delhi Rajiv Gandhi Cancer Institute & Research Center, India · Tests: neoadjuvant chemotherapy, curative surgery A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors NCT06043466Phase 12 sites📍 Hangzhou📍 Hangzhou Chongqing Precision Biotech Co., Ltd · Tests: CEA-targeted CAR-T cells GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1） NCT06988592n/a1 site📍 Shanghai Fudan University · Tests: GemCis plus PD-1/PD-L1 inhibitor Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma NCT07099547Phase 21 site📍 Hefei Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Tests: ZG005, Tislelizumab, Gemcitabine, Cisplatin Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) NCT05451043Phase 21 site📍 Edmonton AHS Cancer Control Alberta · Tests: Durvalumab, Gemcitabine, Nab paclitaxel, Tremelimumab, Propranolol A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites📍 Sacramento📍 Celebration📍 Miami Marengo Therapeutics, Inc. · Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer NCT05065957Phase 2, Phase 35 sites📍 Kaohsiung City📍 Taichung📍 Taipei InnoPharmax Inc. · Tests: D07001-softgel capsules + Xeloda (or TS-1), mFOLFOX A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio NCT05655949Phase 21 site📍 Boston Beth Israel Deaconess Medical Center · Tests: Gemcitabine, Cisplatin, Durvalumab, Yttrium-90

🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy